Why they built it
African populations were underrepresented in genomic research. Founder Abasi Ene-Obong wanted to bring the continent into the global healthcare debate by collecting samples through Nigerian hospitals and processing them locally. The bet was that representative cohorts plus local sequencing, biobanking, and pharmaceutical research could support diagnostics, clinical trials, and drug discovery.
Why it didn't work out
54Gene began winding down in July 2023 because it could not continue to operate financially. Pandemic diagnostics had produced near-term revenue while the core genomics and pharmaceutical model required sustained capital over much longer timelines. When testing demand fell, the core business had not produced publicly verified revenue at scale to replace it.
What went wrong
Most important first.
- 1
COVID revenue collapsed before genomics paid Monetization
COVID-19 diagnostics generated near-term revenue, but when demand declined the company cut 95 roles mostly from the COVID laboratory and sales operation and the slower pharmaceutical business had no publicly verified revenue to replace it.
- 2
Pharma R&D never converted to verified deals Product-market fit
The packet verifies no drug targets, licensed assets, milestone payments, or clinical-stage therapeutic programs, and described work with U.S. and European pharmaceutical companies named no customers, scope, values, or recognized revenue.
- 3
Capital ran out after reported down round Capital
After more than $45 million in disclosed funding including a $25 million Series B, a reported down round cut valuation from roughly $170 million or $175 million to about $50 million and 2023 fundraising and partnership goals did not prevent wind-down.
- 4
Leadership turnover and repeated layoffs Team
Ene-Obong stepped down as CEO in October 2022, Teresia Bost became interim CEO, Ron Chiarello became CEO in March 2023, and the company cut roughly 25 percent of remaining staff that month before winding down in July.
- 5
Biobank custody outlived the company Regulation
Samples and data retained consent, storage, legal-control, and access obligations after financing ended, and 2025 reporting said a Lagos injunction blocked a proposed $3 million asset sale involving biodata associated with 100,000 Nigerians without establishing final custody, funding, or controller.
What could be different today
- A 2025 Lagos injunction blocking a proposed $3 million sale involving biodata associated with 100,000 Nigerians makes custodian, legal controller, storage funding, and transfer restrictions an explicit diligence item in any biobank wind-down.
- A 2026 peer-reviewed review now frames private biobanks as requiring long-term stewardship and research funding that can conflict with venture-return timelines.
- The 449-person whole-genome resource with CRAM and aggregate VCF files in the European Genome-phenome Archive under controlled non-commercial use through the NCD-GHS consortium provides a working example of narrow-dataset governance separate from the full biobank.
- H3Africa is identified as a major public capacity program and BioVana as a newer Nigerian initiative, changing the institutional landscape for partners and comparators since 2019.
